

## References

### I-40

1. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol* 2016; 17:791–800.
2. Perez, EA, Barrios C, Wiermann W, et al. trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2–positive, advanced breast cancer: Primary results from the Phase III MARIANNE study. *J Clin Oncol*. 2016;141-148.
3. MICROMEDEX®SOLUTIONS Compendia. 2021. Pertuzumab.
4. Clinical Pharmacology Compendia. 2021 Tampa FL: Gold Standard, Inc. Pertuzumab.
5. Perjeta (pertuzumab) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 02/2021
6. Tiwari S, Mishra P, Raska P, et al. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic her2- positive breast cancer. *Breast Cancer Res Treat*. 2016;158:189-193.
7. Urruticoechea A, Rizwanullah M, Im S, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. *J Clin Oncol*. 2017;35:3030-3038.
8. National Comprehensive Cancer Network (NCCN). Pertuzumab. NCCN Drugs and Biologics Compendium®. 2021
9. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2- amplified metastatic colorectal cancer: an updated report from a multicenter, open-label, phase 2a, multiple basket study. *The Lancet*. 2019;20(4):518-530.

10. Wang R, Smyth LM, Iyengar N, et al. Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow- *Oncologist*. 2019;24(8):646-652.
11. Kurzock R, Bowles DW, Kang H, Meric-Bernstam F, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from My Pathway, a phase IIa multiple basket study. *Ann Oncol*. 2020;31:412-421.
12. Pertuzumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 02/09/2021.
13. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.